Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis, with a ...

OBJECTIVES: To evaluate the effect of minocycline as treatment for cutaneous calcinosis in limited cutaneous systemic sclerosis (lcSSc). METHODS: Patients with lcSSc who had cutaneous calcinosis ...

Health charity Scleroderma & Raynaud's UK (SRUK) is urging the public to take a 60-second online test to find out if they may ...

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse ...

limited systemic sclerosis accounted for 66% of total cases, followed by diffuse systemic sclerosis in the US in 2023. . In age-specific cases, the 40–69 age group represented the highest ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing systemic sclerosis.

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

Systemic scleroderma, also known simply as scleroderma ... In some cases, it progresses slowly and is limited to the skin, while in others, it rapidly attacks internal organs such as the lungs ...

As an orally available inhibitor of endothelin-1, which has been implicated in the pathogenesis of vascular disease in systemic sclerosis (SSc), bosentan is widely used as first-line therapy for ...